BORTEZOMIB HYDRATE |
VELCADE |
LDP-341 |
BORTEZOMIB |
NSC-681239 |
PS-341 |
PS 341 |
N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE |
VELCADE® |
PEPTIDE BORONATE |
[(1R)-3-METHYL-1-({(2S)-3-PHENYL-2-[(PYRAZIN-2-YLCARBONYL)AMINO]PROPANOYL}AMINO)BUTYL]BORONIC ACID |
drugbank:00188 |
rxcui:358258 |
chembl:CHEMBL325041 |
chemidplus:179324-69-7 |
pubchem.compound:387447 |
Year of Approval | 2003 |
Drug Class | antineoplastic agents |
FDA Approval | Multiple myeloma, Mantle cell lymphoma |
Drug Class | Small molecule inhibitor |
Drug Categories | cytochrome p-450 cyp1a2 inhibitors (moderate) |
Drug Categories | boronic acids |
Drug Categories | boron compounds |
Drug Categories | acids |
FDA Approval | approved |
Drug Class | Small Molecule |
Drug Indications | antineoplastic agent |
Drug Categories | cardiotoxic antineoplastic agents |
Drug Categories | cytochrome p-450 cyp1a2 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 cyp2c19 inhibitors (weak) |
Drug Categories | cytochrome p-450 cyp2c9 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 cyp3a substrates |
Drug Categories | cytochrome p-450 cyp3a4 substrates with a narrow therapeutic index |
Drug Categories | cytochrome p-450 enzyme inhibitors |
Drug Categories | cytochrome p-450 substrates |
Drug Categories | hepatotoxic agents |
Drug Categories | immunosuppressive agents |
Drug Categories | narrow therapeutic index drugs |
Drug Categories | oatp1b3 inhibitors |
Drug Categories | p-glycoprotein substrates |
Drug Categories | p-glycoprotein substrates with narrow therapeutic index |
Drug Categories | potential qtc-prolonging agents |
Drug Categories | proteasome inhibitors |
Drug Categories | qtc prolonging agents |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
Trial Name | Velcade |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | 26S proteosome inhibitor |
Trial Name | Velcade |
inhibitor (inhibitory) |
Novel drug target | Established target |
Trial Name | Velcade |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | 26S proteosome inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Novel drug target | Established target |
Trial Name | Velcade |
Direct Interaction? | True |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | 26S proteosome inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
Trial Name | Velcade |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | 26S proteosome inhibitor |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
Notes |
inhibitor (inhibitory) |
Notes |
n/a |
inhibitor (inhibitory) |
BORTEZOMIB | Primary Drug Name |
Drug Class | antineoplastic agents |
Year of Approval | 2003 |
LDP341 | Development Name |
MLN341 | Development Name |
PS-341 | Development Name |
Drug Class | Small molecule inhibitor |
FDA Approval | Multiple myeloma, Mantle cell lymphoma |
BORTEZOMIB | DrugBank Drug Name |
179324-69-7 | CAS Number |
Act Bortezomib | Drug Brand |
Drug Type | small molecule |
Drug Groups | approved |
Drug Groups | investigational |
Drug Indications | antineoplastic agent |
Drug Class | Small Molecule |
FDA Approval | approved |
CHEMBL325041 | ChEMBL Drug ID |
C1851 | NCI drug code |
C1851 | NCI drug code |
D03AJX | TTD Drug ID |
BORTEZOMIB | Primary Drug Name |
BORTEZOMIB | Drug Generic Name |
VELCADE | Drug Trade Name |
D0SH3I | TTD Drug ID |
BORTEZOMIB | GuideToPharmacology Ligand Name |